07:57 AM EDT, 08/22/2024 (MT Newswires) -- Biogen (BIIB) and Eisai's drug lecanemab for the treatment of early-stage Alzheimer's disease may not be used by the UK National Health Service as its benefits are "too small to justify the costs," the National Institute for Health and Care Excellence said Thursday.

Lecanemab secured approved from the UK's Medicines and Healthcare products Regulatory Agency early Thursday.

However, the independent committee ruled that it cannot be considered good value for taxpayer money as it is not a cost-effective use of limited NHS funding, therefore it does not recommend lecanemab for use in the NHS.

Clinical trial evidence shows that lecanemab on average provides four to six months slowing in the rate of progression from mild to moderate Alzheimer's disease.

Price: 207.13, Change: +0.95, Percent Change: +0.46